Today, Bristol-Myers Squibb’s (BMY) “Buy” Rating Reiterate at Citigroup Inc.

Today, Bristol-Myers Squibb’s (BMY) “Buy” Rating Reiterate at Citigroup Inc.
Bristol-Myers Squibb Co. (NYSE:BMY)‘s stock had its “buy” rating restated by research analysts at Citigroup Inc. in a report released on Tuesday.

Several other brokerages have also recently issued reports on BMY. Jefferies Group increased their target price on Bristol-Myers Squibb from $77.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, July 14th. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research report on Wednesday, July 13th. Berenberg Bank reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, July 12th. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 target price on the stock in a research report on Monday, July 25th. Finally, SunTrust Banks Inc. lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $86.00 to $68.00 in a report on Friday, August 5th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $67.51.

Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 56.98 on Tuesday. The company has a market cap of $95.23 billion, a price-to-earnings ratio of 28.50 and a beta of 0.90. The company has a 50 day moving average price of $52.69 and a 200 day moving average price of $63.10. Bristol-Myers Squibb has a one year low of $49.03 and a one year high of $77.12.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.12. The business had revenue of $4.83 billion for the quarter, compared to analysts’ expectations of $4.76 billion. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. The business’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.39 EPS. Equities analysts predict that Bristol-Myers Squibb will post $2.85 EPS for the current year.

In related news, Director Lamberto Andreotti sold 21,600 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $56.87, for a total value of $1,228,392.00. Following the sale, the director now directly owns 334,499 shares in the company, valued at approximately $19,022,958.13. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.24% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the company. Bank of Montreal Can purchased a new stake in Bristol-Myers Squibb during the second quarter valued at about $154,732,000. IBM Retirement Fund raised its position in Bristol-Myers Squibb by 1.1% in the second quarter. IBM Retirement Fund now owns 219,448 shares of the biopharmaceutical company’s stock worth $16,627,000 after buying an additional 2,421 shares during the period. Essex Investment Management Co. LLC raised its position in Bristol-Myers Squibb by 0.3% in the second quarter. Essex Investment Management Co. LLC now owns 225,829 shares of the biopharmaceutical company’s stock worth $16,610,000 after buying an additional 574 shares during the period. HL Financial Services LLC raised its position in Bristol-Myers Squibb by 0.8% in the second quarter. HL Financial Services LLC now owns 360,221 shares of the biopharmaceutical company’s stock worth $26,494,000 after buying an additional 2,901 shares during the period. Finally, PGGM Investments raised its position in Bristol-Myers Squibb by 1.3% in the second quarter. PGGM Investments now owns 1,321,858 shares of the biopharmaceutical company’s stock worth $97,223,000 after buying an additional 17,200 shares during the period. Institutional investors own 71.28% of the company’s stock.

Bristol-Myers Squibb Company Profile

Related posts

Leave a Comment